Investor Conference Call
|
|
- Leo Bates
- 5 years ago
- Views:
Transcription
1 Investor Conference Call FY/Q Results February 26, 2015 / Marijn Dekkers, CEO Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 2 Q4/FY 2014 Investor Conference Call Marijn Dekkers
2 2014 Strong Business Development and Focus on Life Sciences Delivered strong organic growth with record earnings; all subgroups contributed Q4 product innovations and emerging markets continued to drive performance Portfolio transformation into a pure Life Science Company underway Integration of acquired businesses on track Dividend proposal of 2.25, up 7% yoy, 37% payout of Core EPS Financial outlook 2015 projects further growth and higher earnings Page 3 Q4/FY 2014 Investor Conference Call Marijn Dekkers Q Solid Finish to a Successful Year % currency & portfolio adj. EBIT EBITDA Before special items Core EPS in 9,888 11,039 1,769 1, % -14% +4% +8% Page 4 Q4/FY 2014 Investor Conference Call Marijn Dekkers
3 Q Divisional Break-Down % currency & portfolio adj. +5% Pharma +10% EBITDA Before special items 1,609 1,769 2,948 3, EBITDA 1, % +14% 3, % +8% 2,195 2,327 Group 11,039m; +7% Consumer Health +4% , % -13% Page 5 Q4/FY 2014 Investor Conference Call Marijn Dekkers FY 2014 All Targets Achieved Fx & portf. adjusted, EBITDA before special items 2014 Guidance 2014 Actual 2014 Actual vs ~5% to ~ 41-42bn 42.2bn +7% adj. EBITDA mid-single-digit % 8.8bn +5% core EPS mid-to-high-single-digit % % Page 6 Q4/FY 2014 Investor Conference Call Marijn Dekkers
4 FY 2014 Recently Launched Products Continued to Drive Performance at Pharma % currency & portfolio adj. Product % currency adj. Established products -2% +82% 1, % 9,144 2, Recently launched +95% +17% % 157 nm 89 Pharma 12,052m; +11% Xarelto Eylea Stivarga Page 7 Q4/FY 2014 Investor Conference Call Marijn Dekkers Consumer Care Brands and Emerging Market Focus Countries Drive Growth 5.6bn 3.9bn +5%** +10% +18% pro-forma* China Brazil Russia +28% +26% +26% % Fx adj. yoy Page 8 FY/Q Investor Conference Call Marijn Dekkers * including acquired businesses ** including Aspirin Cardio recognized at Pharma
5 FY 2014 Commercial Execution, New Products, and Seeds Drive Growth At In million, % yoy currency & portfolio adj. New CP Product * Seeds +20% Environmental Science +7% 1, Crop Protection +11% 7,712 in bn % Seed % 1, ,494m; +11% Page 9 Q4/FY 2014 Investor Conference Call Marijn Dekkers * Launched since 2006; nominal growth FY 2015 Group Guidance Further and Earnings Growth Fx and portfolio adjusted, EBITDA before special items e* adj. EBITDA 42.2bn 8.8bn Low-single digit % ~ 46bn (positive FX effect approx. +3%) Low-to-mid-teens % (positive FX effect approx. +2%) core EPS 6.02 Low-teens % (positive FX effect approx. +3%) Page 10 Q4/FY 2014 Investor Conference Call Marijn Dekkers *Assuming Fx rates of 12/31/2014 (USD 1.21) Outlook depends on specific planning assumptions as detailed in the Annual Report
6 FY 2015 R&D and CapEx Budgets R&D 2015e: > 4.0bn (+10%) CapEx (PPE) 2015e: ~ 2.3bn HealthCare ~ 2.6n thereof Pharma ~ 2.2bn ~ 0.2bn 5% ~ 1.1bn HealthCare ~ 0.8bn 35% ~ 0.5bn 23% 66% 27% 2% Reconciliation ~ 0.1bn Reconciliation ~ 0.3bn 11% 31% ~ 0.7bn Page 11 Q4/FY 2014 Investor Conference Call Marijn Dekkers FY 2015 Guidance by Subgroup Guidance cpa* Adj. EBITDA Guidance* HealthCare Mid-single-digit % (FX +3%) Mid-teens % Pharma Consumer Health Mid-to-high-single-digit % (FX +2%) Launch product sales: towards 4bn Mid-single-digit % (FX +3%) Low-teens % Slight margin improvement Mid-to-high twenties % Low-to-mid-single-digit % (FX +4%) Low-to-mid-single-digit % Lower sales, as volume growth is over compensated by lower selling prices Significant CFROI WACC Page 12 Q4/FY 2014 Investor Conference Call Marijn Dekkers *Assuming Fx rates of 12/31/14 (USD 1.21) Fx & portf. adjusted, EBITDA before special items Outlook depends on specific planning assumptions as detailed in the Annual Report
Investor Conference Call
Investor Conference Call FY/Q4 2015 Results February 25, 2016 / Marijn Dekkers, CEO Page 1 Q4/FY 2015 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements
More informationInvestor Conference Call
Investor Conference Call Q3 2014 Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q3 2014 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements
More informationSeptember 18, 2014 / Marijn Dekkers, CEO
Transforming Bayer into a Pure Life Company - Exit of Material September 18, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers September 18, 2014 Disclaimer This presentation may
More informationInvestor Conference Call Q Results
Science For A Better Life Investor Conference Call Q1 2009 Results Werner Wenning, CEO April 29 2009 Q1 2009 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking
More informationInvestor Conference Call FY/Q Results
For A Better Life Investor Conference Call FY/Q4 2006 Results Werner Wenning, CEO March 15 2007 Disclaimer This presentation contains forward-looking statements based on current assumptions and forecasts
More informationInvestor Conference Call FY/Q Results
Science For A Better Life Investor Conference Call FY/Q4 Results Werner Wenning, CEO February 26 2010 FY/Q4 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking
More informationInvestor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to
More informationQ Analyst and Investor Briefing September 5, 2018
Q2 218 Analyst and Investor Briefing September 5, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer completes biggest acquisition in its history Monsanto business included
More informationInvestor Conference Call
Investor Conference Call /////////// Q2 2018 Results September 05, 2018 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information Certain statements contained
More informationQ Analyst and Investor Briefing July 31, 2012
Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has outstanding perspectives as a pure
More informationInvestor Conference Call
Investor Conference Call Q3 2017 Results October 26, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute
More informationInvestor News. Another record year for Bayer. Fiscal 2015:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation
More informationQ Analyst and Investor Briefing February 26, 2010
Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price
More informationQ Analyst and Investor Briefing February 28, 2018
Q4 217 Analyst and Investor Briefing February 28, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Q4 217: Sales at 8,596 million (+2.7% Fx & portf. adj.) EBITDA before special
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2018 Financial Summary for Investors and Analysts A year of investments and delivery on Guidance Healthcare Solid organic growth of 5.2% driven by resilient core business with 3% organic growth
More informationQ Analyst and Investor Briefing October 27, 2009
Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped
More informationQ Analyst and Investor Briefing October 28, 2010
Q3 21 Analyst and Investor Briefing October 28, 21 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Further growth in Group sales and underlying EBITDA mainly driven by business
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2016 Financial Summary for Investors and Analysts A successful year: Healthcare solid commercial performance and first pipeline filings Life Science above-market growth amid seamless integration
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2017 Financial Summary for Investors and Analysts Performance amid headwinds: Healthcare sound core business; successful launches of Mavenclad & Bavencio Life Science strong performance above
More informationQ Analyst and Investor Briefing July 28, 2011
Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price
More informationQ Analyst and Investor Briefing March 3, 2009
Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by
More informationof 5 01/08/ :58
July 31, 2012 Strong business performance in the second quarter of 2012: Sales increased by 10.0 percent to a record EUR 10,177 million / CropScience and HealthCare sustained strong momentum, MaterialScience
More informationAcquisition of Merck s Consumer Care Business & Pharma sgc Cooperation
Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Investor Conference Call May 6, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers May 6, 2014 Disclaimer This
More informationQ Analyst and Investor Briefing April 29, 2009
Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by
More informationQ Financial Summary for Investors and Analysts
Page 1 o Q1 2017 Financial Summary for Investors and Analysts Solid start in a challenging year Healthcare sound base business, first Bavencio approvals & further pipeline progress Life Science solid growth
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
News Release Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer
More informationDr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful
More informationFinancial Targets through 2022: Focus on Value Creation
Financial Targets through 2022: Focus on Value Creation /////////// Capital Markets Day London, December 5, 208 Wolfgang Nickl CFO Bayer AG Disclaimer Cautionary Statements Regarding Forward-Looking Information
More informationNews Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial and innovation targets for 2011 achieved Bayer: sales and EBIT at record levels Sales increase
More informationMerck FY/Q Financial Summary for Investors and Analysts
Merck FY/Q4 2014 Financial Summary for Investors and Analysts Strategic progress and delivery of results in 2014: Closing and successful integration of AZ Electronic Materials Announcement of Sigma-Aldrich
More informationInvestor Handout Roadshow London Marijn Dekkers, CEO
Investor Handout Roadshow London Marijn Dekkers, CEO May 25-26, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by
More informationCropScience Analyst & Investor Days
CropScience Analyst & Investor Days September 5 & 6, 2005 Lyon, France CropScience Analyst & Investor Days Efficiency Improvement and Business Excellence September 5-6, 2005 Lyon, France Dr. Dirk Suwelack
More informationInvestor Handout Q April 2012 I Leverkusen
Investor Handout Q1 2012 April 2012 I Leverkusen Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup
More informationBayer: Good performance in a challenging environment, Group outlook confirmed
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Third quarter of 2018 Bayer: Good performance in a challenging environment, Group outlook confirmed Group sales
More informationQ Earnings Presentation August 2, 2018
Q2 2018 Earnings Presentation August 2, 2018 Safe Harbor Statement Safe Harbor Statement under the Private Securities Act of 1995: Statements in this news release that are forward-looking statements are
More informationInvestor Handout. Roadshow California
Investor Handout Roadshow California July 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup
More informationFY 2014 Results Presentation. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015
FY 2014 Results Presentation Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015 Disclaimer 1. This presentation may contain certain forward-looking statements, including assumptions,
More informationCautionary Statements Regarding Forward-Looking Information
Investor Handout December 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could
More informationInterim Report. Third Quarter of Bayer posts strong earnings growth
Interim Report Third of Bayer posts strong earnings growth 2 Bayer Interim Report Key Data Bayer Group Key Data Change Change Full Year million million % million million % million Sales 9,967 11,036 +
More informationQ Earnings Presentation. Rainer Beaujean, Speaker of the Management Board and CFO April 12, 2018
Q1 2018 Earnings Presentation Rainer Beaujean, Speaker of the Management Board and CFO April 12, 2018 Disclaimer This presentation may contain certain forward-looking statements, including assumptions,
More informationQ Financial Summary for Investors and Analysts
Q2 2014 Financial Summary for Investors and Analysts Sound business performance supported by inorganic growth: Organic sales growth and portfolio outweigh FX headwinds Double-digit growth in Emerging Markets,
More informationPositive momentum continues
Positive momentum continues Q3 2015 Results covestro.com 1 Forward-looking statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Covestro
More informationInvestor Handout. Roadshow Scandinavia
Investor Handout Roadshow Scandinavia June 15/16, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group
More informationBuilding Growth Momentum in HealthCare
Building Growth Momentum in HealthCare Marijn Dekkers, CEO September 20, 2011 UBS Life Science Conference Disclaimer This presentation may contain forward-looking statements based on current assumptions
More informationInterim Report. First Quarter of Strong start to the year for Bayer
Interim Report First Quarter of Strong start to the year for Bayer 2 Bayer Interim Report Key Data Bayer Group Key Data Change Full Year million million % million Sales 10,555 12,117 + 14.8 42,239 Change
More informationBayer: Operational business held back by currency effects Major progress with Monsanto acquisition
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com First quarter of 2018 Bayer: Operational business held back by currency effects Major progress with Monsanto acquisition
More informationLehman Conference, April 2003
Lehman Conference, April 2003 Klaus Kühn, CFO of Bayer AG Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various
More informationInvestor Handout Q2 2013
Investor Handout Q2 2013 August 2013 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown
More informationFirst Quarter 2018 Conference Call
First Quarter 2018 Conference Call Investor Presentation St. Paul, MN March 29, 2018 Safe Harbor & Regulation G 2 Safe Harbor Statement Certain matters discussed today may include 'forward looking statements'
More informationBayer increases sales and earnings in the second quarter
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com MaterialScience leaves the crisis behind Bayer increases sales and earnings in the second quarter Sales
More informationTI Fluid Systems plc Results Presentation for TI Fluid Systems plc 20 March 2018
2017 Results Presentation for 20 March 2018 Disclaimer This presentation contains certain forward-looking statements with respect to the financial condition, results of operations and business of (the
More informationHELLA Investor Update H1 FY 2016/17
HELLA Investor Update 2016/17 Conference Call on January 12th, 2017 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.
More informationQ4 & FY 2017 EARNINGS PRESENTATION MARCH 13, 2018
Q4 & FY 2017 EARNINGS PRESENTATION MARCH 13, 2018 FORWARD-LOOKING STATEMENTS & NON-GAAP FINANCIAL INFORMATION 2 FORWARD-LOOKING STATEMENTS This presentation contains, and management may make on our call
More information2016 Amadeus IT Group SA Results. February 26, 2016
2015 Results February 26, 2016 Disclaimer This presentation may contain certain statements which are not purely historical facts, including statements about anticipated or expected future revenue and earnings
More informationQ Trading Update. May 4, 2016
Q1 2016 Trading Update May 4, 2016 Forward looking statements This Presentation may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management
More informationFUCHS GROUP. Financial Results Analyst s Conference, 21 st March 2018, Frankfurt Stefan Fuchs, CEO Dagmar Steinert, CFO
FUCHS GROUP Financial Results 2017 Analyst s Conference, 21 st March 2018, Frankfurt Stefan Fuchs, CEO Dagmar Steinert, CFO Highlights FY 2017 Sales +9% to 2.5 bn Strong organic growth in Asia-Pacific,
More informationQ Results. Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018
Q3 2018 Results Lars Brorsen (CEO) Christoph Hobo (CFO) November 22, 2018 Agenda 1. Highlights Q3 2018 2. Market outlook 3. Detailed results review 4. Company outlook 5. Q&A Appendix 1 Business summary
More informationNews Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010:
News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial News Conference on fiscal 2010: Bayer: operating performance on track Group targets achieved
More informationFiscal First Quarter 2017 Earnings Conference Call
Fiscal First Quarter 2017 Earnings Conference Call May 5, 2017 Forward-Looking Statements This presentation includes certain statements relating to future events and our intentions, beliefs, expectations,
More informationHELLA Investor Update FY 2017/18
HELLA Investor Update FY 2017/18 Conference Call on August 10, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.
More informationQ presentation. 10 May Nordic market leader in chicken products
Q1 2016 presentation 10 May 2016 Nordic market leader in chicken products 0 Summary of Q1 2016 Strong growth in net sales, particularly in chilled products Continued strong performance in Sweden Substantial
More informationQ Earnings Presentation November 6, 2018
Q3 2018 Earnings Presentation November 6, 2018 Safe Harbor Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release that are forward-looking
More informationQ Analyst & Investor Conference Call
Q2 2012 Analyst & Investor Conference Call Kasper Rorsted, CEO Carsten Knobel, CFO Düsseldorf, Disclaimer This information contains forward-looking statements which are based on current estimates and assumptions
More informationLANXESS FY/Q Financial Summary for Investors and Analysts
LANXESS FY/Q4 2016 Financial Summary for Investors and Analysts Summary FY 2016 Transformation gains traction Significant strategic evolution of the company with the establishment of ARLANXEO Integration
More informationAnother record year for Bayer good progress with the acquisition of Monsanto
News Release Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Fiscal 2016: Another record year for Bayer good progress with the acquisition of Monsanto
More informationHenkel AG & Co. KGaA. Klaus Keutmann Frankfurt,
Henkel AG & Co. KGaA Klaus Keutmann Frankfurt, 21.01.2015 Disclaimer This information contains forward-looking statements which are based on current estimates and assumptions made by the corporate management
More information4Q 2017 Earnings Presentation February 13, 2018
4Q 2017 Earnings Presentation February 13, 2018 Safe Harbor Statement Safe Harbor Statement under the Private Securities Act of 1995: Statements in this news release that are forward-looking statements
More information3Q 2018 OTELLO CORPORATION ASA
3Q 2018 OTELLO CORPORATION ASA Agenda Executive Summary & Operational Review (CEO, Lars Boilesen) Bemobi (CEO Bemobi, Pedro Ripper) Financial Review (CFO, Petter Lade) 2 Executive Summary 3 Quarterly highlights
More informationInterim Results 6-month figures FY 11
Interim Results 6-month figures FY 11 Bernhard Schreier, CEO Dirk Kaliebe, CFO Andreas Trösch, Head of Investor Relations Heidelberger Druckmaschinen AG November 10, 2010 Highlights Q2 FY 11 650 million
More informationSpring Investor Conference 2003
Spring Investor Conference 2003 Rolf Classon, Bayer HealthCare Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
More informationLudwigshafen, February 26, 2016
Ludwigshafen, February 26, 216 Analyst Conference Call FY215 Cautionary note regarding forward-looking statements This presentation may contain forward-looking statements that are subject to risks and
More informationQ1 2017/18 RESULTS PRESENTATION. 13 February 2018
Q1 2017/18 RESULTS PRESENTATION 13 February 2018 DISCLAIMER AND NOTES To the extent that statements in this presentation do not relate to historical or current facts, they constitute forward-looking statements.
More informationStockholders Newsletter Financial Report as of September 30, 2013
Stockholders Newsletter Financial Report as of September 30, k Cover Picture Third quarter of : Bayer continues positive business momentum Contents Interim Group management Report as of September 30,...4
More information2013 Full Year Results Presentation 3 March 2014
2013 Full Year Results Presentation 3 March 2014 Wolfhart Hauser Chief Executive Officer Lloyd Pitchford Chief Financial Officer 1 Lloyd Pitchford Chief Financial Officer Financial Performance 2013 Full
More informationHalf Year results and outlook
PRESENTATION TO INVESTORS & ANALYSTS Half Year results and outlook David Banfield - Group CEO Jannine Mountford - Group CFO 1 March 2018 For 6 months 1 July 31 December 2017 New Zealand tapware underperforms,
More informationHELLA Investor Update Q1 2015/16
HELLA Investor Update Q1 2015/16 Conference Call on September 25th, 2015 Dr. Wolfgang Ollig, Chief Financial Officer Carl Pohlschmidt, Finance Director HF-7761DE_C (2012-12) Disclaimer This document was
More informationInterim Report Q4 FY 17
Interim Report Q4 FY 17 Quarter 4 / Fiscal Year 2017 Sustained positive development Sivantos delivered 3.1% organic growth 1) in Q4 FY2017. The moderate growth rate compared to previous quarters was a
More informationUBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG
UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG September 20, 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and
More informationNews Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016:
News Release Bayer AG Corporate Brand, Communications & Government Relations 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Third quarter of 2016: Bayer shows strong performance Acquisition
More informationQ Analyst & Investor Conference Call
Q1 2012 Analyst & Investor Conference Call Kasper Rorsted, CEO Dr. Lothar Steinebach, CFO London/Düsseldorf, Disclaimer This information contains forward-looking statements which are based on current estimates
More informationZumtobel Group AG Q1 2017/ September 2017
Zumtobel Group AG Q1 2017/18 05 September 2017 Despite stalling growth momentum Group adj. EBIT only slightly below prior year Financials Q1 FY 2017/18 at a glance Group revenues fx-adjusted 0.7% below
More informationSecond Quarter Financial Results Fiscal Year 2017 (Ending March 2018)
Second Quarter Financial Results Fiscal Year 2017 (Ending March 2018) October 26, 2017 SEIKO EPSON CORPORATION 2017. All rights reserved. Disclaimer regarding forward-looking statements The foregoing statements
More informationThird Quarter Financial Results Fiscal Year 2017 (Ending March 2018)
Third Quarter Financial Results Fiscal Year 2017 (Ending March 2018) January 31, 2018 SEIKO EPSON CORPORATION 2018. All rights reserved. Disclaimer regarding forward-looking statements The foregoing statements
More informationResults FY 2017 Schaeffler AG. Conference Call March 7, 2018 Munich
Results FY 2017 Schaeffler AG Conference Call Munich Disclaimer This presentation contains forward-looking statements. The words "anticipate", "assume", "believe", "estimate", "expect", "intend", "may",
More informationConference Call Q Results. Analysts Conference Call 30 April 2015
Conference Call Q1 2015 Results Analysts Conference Call 30 April 2015 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective subsidiaries and businesses.
More information2017 THIRD-QUARTER EARNINGS REVIEW October 24, 2017
2017 THIRD-QUARTER EARNINGS REVIEW October 24, 2017 CAUTIONARY STATEMENT This presentation contains forward-looking statements about Whirlpool Corporation and its consolidated subsidiaries ( Whirlpool
More information1Q19 FINANCIAL RESULTS. November 7, 2018
1Q19 FINANCIAL RESULTS November 7, 2018 1Q19 FINANCIAL HIGHLIGHTS A CHALLENGING QUARTER REFLECTING IMPACT OF DISRUPTION ~2,137 $1,150M (+150M) -90 1Q19 Net Revenue LFL (7.7%), or ~(2.5%) when excluding
More informationANSELL LIMITED Half Year Results to December Magnus Nicolin Chief Executive Officer Neil Salmon Chief Financial Officer
ANSELL LIMITED Half Year Results to December 2014 Magnus Nicolin Chief Executive Officer Neil Salmon Chief Financial Officer Disclaimer The following presentation has been prepared by Ansell Limited for
More informationNon-Deal Debt Roadshow
Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements
More informationZur Rose Group 2017 Results Analyst & Media Conference
Zur Rose Group 2017 Results Analyst & Media Conference Walter Oberhänsli Marcel Ziwica 21 March 2018 Highlights and Lowlights Zur Rose Group Conference call 23 August 2017 3 Highlights and Lowlights Successful
More informationAnalyst & Investor Fact Sheet Q3 2018
Evonik Group in million Q3 2017 yoy Δ% Q2 2018 qoq Δ% External sales 3,556 3,794 7% 3,870 3,794-2% 3,756 Volume (%) -1% 3% Price (%) 9% 4% Exchange Rates (%) -1% -2% Other effects (%) 0% 1% Adjusted EBITDA
More informationAnalyst Conference Drägerwerk AG & Co. KGaA. March 7 th 2019
Analyst Conference Drägerwerk AG & Co. KGaA March 7 th 2019 Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No
More informationInvestor & Analyst Presentation Ful YearResults 30 June2016 For personal use only 25th August 2016 Rebekah O Flaherty - CEO I Jonathan Kenny - CFO
Investor & Analyst Presentation Full YearResults 30 June2016 25th August 2016 Rebekah O Flaherty - CEO I Jonathan Kenny - CFO Agenda 1 Overview 2 Strategic Priorities 3 FY16 Financial Results 4 FY17 Outlook
More informationAnnouncement of Q Results
Announcement of Q3 2008 Results Conference Call October 15, 2008 2:00 p.m. CEST Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0 Disclaimer This presentation may contain certain forward-looking statements,
More informationStockholders Newsletter Financial Report as of March 31, 2013
k Cover Picture Stockholders Newsletter Financial Report as of March 31, First quarter of : Bayer: Life Sciences off to a good start in anniversary year Contents Interim Group management Report as of March
More informationKION Q3 UPDATE CALL Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 14 November 2013
KION Q3 UPDATE CALL 2013 Gordon Riske, CEO Thomas Toepfer, CFO Wiesbaden, 14 November 2013 AGENDA 1 Highlights 2013 Gordon Riske 2 Financial Update Thomas Toepfer 3 Outlook Gordon Riske 14 November 2013
More informationInvestor Conference. London, August 6, First Half 2003 Results
Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION Results for the 6 months ended 31 December 2017 Kevin Slaven CEO Geoff Stephenson CFO www.pmplimited.com.au ABN 39 050 148 644 27 February 2018 TABLE OF CONTENTS Financial Highlights
More informationFebruary 21, Fourth Quarter 2018 Results
February 21, 2019 Fourth Quarter 2018 Results Forward-looking statements This presentation, as well as other statements made by Delphi Technologies PLC (the Company ), contains forward-looking statements
More information